The key COVID-19 findings in oncology, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.
INSIDE THIS MONITOR
32cited sources
10available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY
Cancer treatment delays were linked to higher mortality
The review reported mortality estimates 6% to 13% higher per 4-week delay than with treatment without that additional delay; the cancer and treatment settings behind the range are not identified here.
This systematic review and meta-analysis assessed cancer treatment delay. The cancer types and treatments contributing to the reported range are not available in this summary.
See the evidence
Treatment Delay
+6-13% Mortality increase per 4-week delay
Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087.
Bivalent vaccination was linked to lower reinfection risk in adults with cancer
22.2%
Among adults with cancer, bivalent COVID-19 vaccination showed 22.2% effectiveness against SARS-CoV-2 reinfection compared with unvaccinated adults with cancer.
This nationwide target trial emulation compared adults with cancer who received a bivalent vaccine with unvaccinated adults with cancer; its follow-up period is not available in this summary.
See the evidence
Vaccine effectiveness of bivalent COVID-19 vaccination against reinfection in adults with cancer
22.2% 95% CI: 15.8-28.2%
Kim, Hyun-Kyung et al.. Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in patients with cancer: Evidence from a nationwide target trial emulation.. The Journal of infection. 2026.
Reinfection risk in bivalent vaccinated cancer patients
5.2%
Kim, Hyun-Kyung et al.. Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in patients with cancer: Evidence from a nationwide target trial emulation.. The Journal of infection. 2026.
Kim, Hyun-Kyung et al.. Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in patients with cancer: Evidence from a nationwide target trial emulation.. The Journal of infection. 2026.
Severe COVID-19 rates were higher with active radiotherapy or chemotherapy
Higher rates of severe COVID-19
In England, patients receiving active radiotherapy or chemotherapy had higher rates of severe COVID-19 than patients in the immunosuppressive medication or immunodeficiency groups.
This OpenSAFELY cohort covered England from 2020 to 2024. The direction of the subgroup difference is reported, but its size is not available in this summary.
See the evidence
Active radio- or chemo-therapy (RCT) patients had higher severe COVID-19 rates than immunosuppressive medication or immunodeficiency groups
Higher rates of severe COVID-19
Parker, Edward P K et al.. Factors associated with severe COVID-19 in immunocompromised subgroups in England from 2020 to 2024: an OpenSAFELY cohort study.. EBioMedicine. 2026.
Pooled evidence linked cancer with higher COVID-19 mortality
A systematic review and pooled analysis found higher COVID-19 mortality among patients with cancer, but the reference group is not available in this summary.
The finding concerns patients with cancer and COVID-19. Cancer type and treatment status are not available in this summary.
See the evidence
Higher COVID-19 mortality risk in cancer patients
2.5x
Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and COVID-19: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43-50.
Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and COVID-19: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43-50.
Study-specific findings. Different populations, treatments and follow-up periods can produce different results.
THE RESEARCH, AS IT ARRIVES
Latest studies.
The newest findings added to this collection. The learning from each, already distilled.
Study summaries are not available in this collection yet. The original evidence remains accessible in each monitor.
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 10 findingsOriginal results, comparisons and study details.
6 of 6 source groupsFindings stay together with their study.
SOURCE 011 finding
Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and COVID-19: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43-50.
+6-13%Mortality increase per 4-week delaySource [2]
SOURCE 031 finding
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-2892.
+57%OR 1.57 vs solid tumors (95% CI: 1.15-2.13)Source [3]
SOURCE 061 finding
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918.
Kim, Hyun-Kyung et al.. Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in patients with cancer: Evidence from a nationwide target trial emulation.. The Journal of infection. 2026.
Parker, Edward P K et al.. Factors associated with severe COVID-19 in immunocompromised subgroups in England from 2020 to 2024: an OpenSAFELY cohort study.. EBioMedicine. 2026.
Browse the 32 original sourcesThe complete bibliography behind this monitor.
[1]
Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and COVID-19: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43-50.
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-2892.
ElGohary GM, Hashmi S, Styczynski J, et al. The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2020.
Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893-903.
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918.
Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309-1316.
Pinato DJ, Zambelli A, Aguilar-Company J, et al. Clinical Portrait of the SARS-CoV-2 Epidemic in European Cancer Patients (OnCovid). Cancer Discov. 2020;10(10):1465-1474.
Garassino MC, Whisenant JG, Huang LC, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7):914-922.
COVIDSurg Collaborative. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg. 2020;107(11):1440-1449.
Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023-1034.
Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Netw Open. 2020;3(8):e2017267.
Monin L, Laing AG, Munoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765-778.
Shroff RT, Chalasani P, Wei R, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021;27(11):2002-2011.
Curigliano G, Banerjee S, Cervantes A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31(10):1320-1335.
Ribas A, Sengupta R, Locke T, et al. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discov. 2021;11(2):233-236.
Liang W, Liang H, Ou L, et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern Med. 2020;180(8):1081-1089.
Kim, Hyun-Kyung et al.. Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in patients with cancer: Evidence from a nationwide target trial emulation.. The Journal of infection. 2026.
Parker, Edward P K et al.. Factors associated with severe COVID-19 in immunocompromised subgroups in England from 2020 to 2024: an OpenSAFELY cohort study.. EBioMedicine. 2026.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.